Advertisement

New Delhi: In the aftermath of a tragic incident in Chhindwara, Madhya Pradesh, where a five-month-old infant allegedly died after consuming Ayurvedic medicines, the state’s Ayush Department has seized the drugs and sent samples for testing and other necessary legal actions, the Ayush ministry said.

According to a statement from the Ministry of Ayush, it is actively coordinating with state authorities to ensure the highest standards of safety and quality in Ayush medicines.

The Ministry of Ayush said it is committed to ensuring the safety and quality standards of Ayush medicines and issues necessary directions to the state and Union Territory (UT) governments for ensuring the compliance of provisions under Drugs and Cosmetics Act 1940 and Drug Rules, 1945 from time to time, PTI reported.
Enforcement of the legal provisions pertaining to Quality Control and issuance of drug licence of Ayurveda, Siddha, Unani, Sowa-Rigpa and Homoeopathy drugs/ medicines is vested with the State Drug Controllers/ State Licensing Authorities appointed by the concerned state and UT governments, the statement said.
The respective state and UT licensing authority is empowered to act against misbranded, adulterated and spurious Ayush drugs.
"As per the information received from the Drug Control Department Ayush, State Government of Madhya Pradesh, immediate actions have been taken in this regard, including seizure of the alleged drugs and sending the sample for testing and other necessary legal actions," the statement said.

The latest death incident comes barely two weeks after a series of child deaths linked to a toxic cough syrup 'Coldrif'. The latest death has taken the toll from the use of liquid formulations to 25.

Earlier, 24 children, comprising 21 from Chhindwara, two from Betul and one from Pandhurna, died of renal failure linked to consumption of 'Coldrif', an allopathic cough syrup found to contain 48.6 per cent diethylene glycol, a highly poisonous compound.

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .